Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2

Biochem Biophys Res Commun. 1999 May 27;259(1):97-102. doi: 10.1006/bbrc.1999.0715.

Abstract

Bone morphogenic protein-2 (BMP-2) is a member of the transforming growth factor beta (TGF-beta) superfamily. While BMP-2 is capable of inducing bone formation ectopically, little is known about its role on osteoclastogenesis. In this study, we examined the effect of BMP-2 on osteoclast-like multinucleated cell (OCL) formation in cocultures of osteoblast-like cells and hematopoietic cells of bone marrow origin. BMP-2 alone did not stimulate OCL formation in this culture system; however, it strongly enhanced OCL formation in a dose-dependent fashion in the presence of interleukin-1alpha (IL-1alpha). Western blot analysis showed that a simultaneous addition of BMP-2 and IL-1alpha synergistically enhanced cyclooxygenase-2 (COX-2) expression in osteoblast-like cells. Moreover, Northern blot analysis revealed that the level of osteoclast differentiation factor (ODF) mRNA increased by treatment with BMP-2 and IL-1alpha in osteoblast-like cells. It is noted that BMP-2 alone did cause an increase in the expression of both COX-2 and ODF genes. The stimulatory effect of BMP-2 was abolished by adding nonsteroidal anti-inflammatory drugs, such as indomethacin and a selective COX-2 inhibitor NS-398. Addition of NS-398 inhibited the expression of the ODF gene in osteoblast-like cells treated with BMP-2 and IL-1alpha. These results indicated that the combination of BMP-2 and IL-1alpha stimulated osteoblast-like cells to elevate the expression of both COX-2 and ODF genes, resulting in an enhanced OCL formation. Since BMP-2 alone induced the expression of COX-2 and ODF genes in osteoblast-like cells, it appears to be one of the regulating factors of osteoclastogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activins
  • Animals
  • Bone Development / drug effects
  • Bone Marrow Cells
  • Bone Morphogenetic Protein 2
  • Bone Morphogenetic Proteins / pharmacology*
  • Carrier Proteins / metabolism*
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacology
  • Gene Expression Regulation, Developmental
  • Indomethacin / pharmacology
  • Inhibins / pharmacology
  • Interleukin-1 / pharmacology*
  • Isoenzymes / metabolism*
  • Membrane Glycoproteins / metabolism*
  • Mice
  • Mice, Inbred Strains
  • Nitrobenzenes / pharmacology
  • Osteoclasts / physiology*
  • Prostaglandin-Endoperoxide Synthases / metabolism*
  • RANK Ligand
  • RNA, Messenger / metabolism
  • Receptor Activator of Nuclear Factor-kappa B
  • Sulfonamides / pharmacology
  • Transforming Growth Factor beta / pharmacology
  • Up-Regulation / genetics

Substances

  • Bmp2 protein, mouse
  • Bone Morphogenetic Protein 2
  • Bone Morphogenetic Proteins
  • Carrier Proteins
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Interleukin-1
  • Isoenzymes
  • Membrane Glycoproteins
  • Nitrobenzenes
  • RANK Ligand
  • RNA, Messenger
  • Receptor Activator of Nuclear Factor-kappa B
  • Sulfonamides
  • Tnfrsf11a protein, mouse
  • Tnfsf11 protein, mouse
  • Transforming Growth Factor beta
  • Activins
  • N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
  • Inhibins
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Indomethacin